Xifaxan Tablet
Product Images NDC 55154-6777

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Xifaxan (NDC 55154-6777). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

926536d5 4f6a 4c56 B05d 7e2149743ada 00

Label for XIFAXAN tablets containing 550 mg of rifaximin. The label indicates a package size of approximately 360 tablets and includes usage, storage, and handling instructions, along with manufacturer and distributor information. It displays the NDC barcode and warnings to keep out of reach of children. The labeler is Cardinal Health 107, LLC.*

FDA Label Image

Chemical Structure (Image 01)

Chemical structure of rifaximin, the active ingredient in XIFAXAN 550 mg oral tablets by Cardinal Health 107, LLC. The diagram depicts the molecular arrangement and bonding of rifaximin.*

FDA Label Image

Figure 1 (Image 02)

A Kaplan-Meier survival curve chart depicting the proportion of patients without breakthrough HE (hepatic encephalopathy) over 168 days post-randomization. The chart compares XIFAXAN and placebo groups, showing a higher sustained proportion for XIFAXAN. The figure includes hazard ratio, 95% confidence interval, and p-value statistics.*

FDA Label Image

Figure 2 (Image 03)

A Kaplan-Meier plot showing the proportion of patients without HE-related hospitalization over days post-randomization, comparing XIFAXAN 550 mg tablets to placebo. The y-axis represents the proportion of patients without hospitalization, and the x-axis shows days post-randomization up to 168 days. The graph includes hazard ratio, confidence interval, and log-rank p-value statistics in a boxed inset.*

FDA Label Image

Bottle Label (Image 04)

A clinical study flow diagram showing phases for a treatment involving placebo (PBO) and rifaximin (RFX). It includes Screening/Treatment 1 Phase, Treatment 2 Phase (2 weeks RFX, 4 weeks follow-up), Maintenance Phase 1 (up to 18 weeks), randomization into Treatment 3 Phase/DBR Treatment Phase, Maintenance Phase 2 (6 weeks), Treatment 4 Phase/SRT Phase, and Follow-up (4 weeks). The diagram highlights symptom diary collection and primary efficacy analysis periods.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.